Silvio Veronese

Silvio Veronese

Auto-generated profile, based on publicly available information

Silvio Veronese

Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milano, Italy

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2014 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
CBChetan Bettegowda
Chetan Bettegowda
MSMark Sausen
Mark Sausen
RLRebecca J. Leary
Rebecca J. Leary
IKIsaac Kinde
Isaac Kinde
YWYuxuan Wang
Yuxuan Wang
LDLuis A. Diaz
Luis A. Diaz
The development of noninvasive methods to detect and monitor tumors continues to be a major challenge in oncology. We used digital polymerase chain reaction–based technologies to evaluate the ability of circulating tumor DNA (ctDNA) to detect tumors in 640 patients with various cancer types. We found that ctDNA was detectable in >75% of patients with advanced pancreatic, ovarian, colorectal, bladder, gastroesophageal, breast, melanoma, hepatocellular, and head and neck cancers, but in less than 50% of primary brain, renal, prostate, or thyroid cancers. In patients with localized tumors, ctDNA was detected in 73, 57, 48, and 50% of patients with colorectal cancer, gastroesophageal cancer, pancreatic cancer, and breast adenocarcinoma, respectively. ctDNA was often present in patients without detectable circulating tumor cells, suggesting that these two biomarkers are distinct entities. In a separate panel of 206 patients with metastatic colorectal cancers, we showed that the sensitivity of ctDNA for detection of clinically relevant KRAS gene mutations was 87.2% and its specificity was 99.2%. Finally, we assessed whether ctDNA could provide clues into the mechanisms underlying resistance to epidermal growth factor receptor blockade in 24 patients who objectively responded to therapy but subsequently relapsed. Twenty-three (96%) of these patients developed one or more mutations in genes involved in the mitogen-activated protein kinase pathway. Together, these data suggest that ctDNA is a broadly applicable, sensitive, and specific biomarker that can be used for a variety of clinical and research purposes in patients with multiple different types of cancer.

13 June 2012 in Nature
Verified
Journal Article
Closed access
PDF file
SMSandra Misale
Sandra Misale
RYRona Yaeger
Rona Yaeger
SHSebastijan Hobor
Sebastijan Hobor
ESElisa Scala
Elisa Scala
MJManickam Janakiraman
Manickam Janakiraman
ABAlberto Bardelli
Alberto Bardelli


1 June 2015 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
Giulia SiravegnaGiulia Siravegna
Giulia Siravegna
BMBenedetta Mussolin
Benedetta Mussolin
MBMichela Buscarino
Michela Buscarino
GCGiorgio Corti
Giorgio Corti
ACAndrea Cassingena
Andrea Cassingena
ABAlberto Bardelli
Alberto Bardelli

1 May 2005 in The Lancet Oncology
Verified
Journal Article
Closed access
MMMauro Moroni
Mauro Moroni
SVSilvio Veronese
Silvio Veronese
SBSilvia Benvenuti
Silvia Benvenuti
GMGiovanna Marrapese
Giovanna Marrapese
Andrea Sartore-BianchiAndrea Sartore-Bianchi
Andrea Sartore-Bianchi
ABAlberto Bardelli
Alberto Bardelli

15 March 2007 in Cancer Research
Verified
Journal Article
Open access
PDF file
SBSilvia Benvenuti
Silvia Benvenuti
Andrea Sartore-BianchiAndrea Sartore-Bianchi
Andrea Sartore-Bianchi
Federica Di NicolantionioFederica Di Nicolantionio
Federica Di Nicolantionio
CZCarlo Zanon
Carlo Zanon
MMMauro Moroni
Mauro Moroni
ABAlberto Bardelli
Alberto Bardelli
Monoclonal antibodies (mAbs) against the extracellular domain of the epidermal growth factor receptor (EGFR) have been introduced for the treatment of metastatic colorectal cancer (mCRC). We have reported recently that increased copy number of the EGFR can predict response to anti-EGFR mAbs and that patients might be selected for treatment based on EGFR copy number. Here, we show that mutations activating the RAS/RAF signaling pathway are also predictive and prognostic indicators in mCRC patients, being inversely correlated with response to anti-EGFR mAbs. In cellular models of CRCs, activation of the RAS signaling pathway by introduction of an activated K-RAS allele (Gly12Val) impairs the therapeutic effect of anti-EGFR mAbs. In cancer cells carrying constitutively active RAS, the pharmacologic inhibition of the mitogen-activated protein kinase (MAPK) signaling cascade improves anti-EGFR treatment based on mAbs. These results have implications for the identification of patients who are likely to respond to anti-EGFR treatment. They also provide the rationale for combination therapies, targeted simultaneously to the EGFR and RAS/RAF/MAPK signaling pathways in CRC patients. [Cancer Res 2007;67(6):2643–8]